SEC Tracker
Get the app

Iridex IRIX

Iridex FY 2020: revenue $36.3M; diluted EPS −$0.46

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.19
Material contract

Key figures from this report

These are the numbers Iridex reported for the year ended Jan 2, 2021, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$36.3MNo year-earlier figure tagged10-K income statement, on EDGAR
  2. Net income−$6.3MNo year-earlier figure tagged10-K income statement, on EDGAR
  3. Diluted EPS−$0.46No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$11.6MNo year-earlier figure tagged10-K balance sheet, on EDGAR
  5. Cash from operations−$3.2MNo year-earlier figure tagged10-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Iridex files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.

  1. Nexalin Technology NXL public float $15M, Jun 30, 2025
  2. Biotricity BTCY public float $13M, Sep 30, 2025
  3. Beyond Air XAIR public float $16M, Sep 30, 2025
  4. RetinalGenix Technologies RTGN public float $16M, Jun 30, 2025
  5. Harvard Apparatus Regenerative Technology HRGN public float $16M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.